Quick-Med Technologies Inc.
902 NW 4th Street
Gainesville,
FL 32601
United States - Map
Phone: 352-379-0611
Fax: 352-379-1099
Web Site: http://www.quickmedtech.com
| Quick-Med Technologies, Inc., a life sciences company, develops technologies for the medical and consumer healthcare markets in the United States. The companys technologies under development include NIMBUS, a family of organic molecules or polymers that are bio-engineered to have antimicrobial, hemostatic, and other properties, which could be used in a range of medical device applications, including contact lenses, wound dressings, incontinence products, or disposable gloves; and Stay Fresh, a chemical formulation for textiles that provides a durable antimicrobial agent, which can be bonded to fibers or fabrics so as to retain the biocidal property through various launderings and is suitable for a range of applications, including apparel, sportswear, active wear, and work wear, as well as furnishings, such as linens, drapes, and towels. Its other technologies under development comprise NimbuDerm, a novel copolymer used as a persistent hand sanitizer; and MultiStat, a family of matrix metalloproteinase inhibitors that are used for the maintenance, healing, and repair of skin and eyes. The company was formerly known as Above Average Investments, Ltd. and changed its name to Quick-Med Technologies, Inc. in February 2002. Quick-Med Technologies, Inc. was founded in 1997 and is headquartered in Gainesville, Florida. |
|
| Key Statistics |
| |
| | Pay | Exercised | Mr. J. Ladd Greeno , 60
Chief Exec. Officer, Director, Chairman of Licensing Committee and Chairman of Exec. Committee |
N/A
| N/A | Mr. Nam H. Nguyen CPA, P.A., 52
Chief Financial Officer and Principal Accounting Officer |
N/A
| N/A | Dr. Gerald M. Olderman Ph.D., 76
VP of R&D & Commercialization, Director and Member of Compensation Committee |
N/A
| N/A | Maj. Gen. George E. Friel , 66
VP of Chemical & Biological Affairs, Director, Chairman of Audit Committee, Chairman of Compensation Committee and Member of Exec. Committee |
$
0 | N/A | Prof. Gregory S. Schultz Ph.D., 58
VP of Laboratory & Clinical Research, Director and Member of Licensing Committee |
$
0 | N/A |
|
|
|
Dollar amounts are as of
31-Dec-09
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.22% Nasdaq 
Profile
